Photocure ASA (PHO) NOK0.5
- Add to watchlist
- This stock can be held in a
Business summary
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Contact details
Important dates
General stock information
- Short code:
- PHO
- ISIN:
- NO0010000045
- Market cap:
- 1.48 billion NOK
- Shares in issue:
- 27.11 million
- Sector:
- Pharmaceuticals
- Exchange:
- Oslo Stock Exchange
- Country:
- Norway
- Currency:
- Norwegian Krone
- Indices:
- Oslo All Share Index
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.